Novel |
ACTB |
actin beta |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Gap junction degradation
- Formation of annular gap junctions
- Regulation of actin dynamics for phagocytic cup formation
- Regulation of actin dynamics for phagocytic cup formation
- HATs acetylate histones
- Prefoldin mediated transfer of substrate to CCT/TriC
- Folding of actin by CCT/TriC
- EPHB-mediated forward signaling
- EPH-ephrin mediated repulsion of cells
- Adherens junctions interactions
- Adherens junctions interactions
- Recycling pathway of L1
- Recycling pathway of L1
- VEGFA-VEGFR2 Pathway
- Interaction between L1 and Ankyrins
- Interaction between L1 and Ankyrins
- Cell-extracellular matrix interactions
- B-WICH complex positively regulates rRNA expression
- RHO GTPases activate IQGAPs
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate Formins
- RHO GTPases Activate Formins
- MAP2K and MAPK activation
- UCH proteinases
- DNA Damage Recognition in GG-NER
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Clathrin-mediated endocytosis
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
- Factors involved in megakaryocyte development and platelet production
|
- Quercetin
- Phenethyl Isothiocyanate
|
- Other phagocyte defects, including the following eight diseases: Chediak-Higashi syndrome; Griscelli syndrome, type 1 (GS1); Griscelli syndrome, type 2 (GS2); Griscelli syndrome, type 3 (GS3); beta-actin deficiency; Neutrophil-specific granule deficiency; Myeloperoxidase deficiency; Glucose 6-phosphate dehydrogenase deficiency; Shwachman syndrome
|
Novel |
AKAP10 |
A-kinase anchoring protein 10 |
- Factors involved in megakaryocyte development and platelet production
|
|
|
Novel |
C1QC |
complement C1q C chain |
- Initial triggering of complement
- Classical antibody-mediated complement activation
- Regulation of Complement cascade
|
- Cetuximab
- Etanercept
- Palivizumab
- Daclizumab
- Bevacizumab
- Zinc
- Copper
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
- Classic complement pathway component defects, including the following eight diseases: C1q alpha-chain deficiency; C1q beta-chain deficiency; C1q gamma-chain deficiency; C1r deficiency; C1s deficiency; C2 deficiency; C3 deficiency; C4 deficiency
|
Novel |
GCK |
glucokinase |
- Regulation of Glucokinase by Glucokinase Regulatory Protein
- Regulation of gene expression in beta cells
- Defective GCK causes maturity-onset diabetes of the young 2 (MODY2)
- Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)
- Glycolysis
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
|
- Beta-D-Glucose
- 2-amino-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide
- 3-[(4-fluorophenyl)sulfanyl]-N-(4-methyl-1,3-thiazol-2-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide
- 2-(methylamino)-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide
- 2-AMINO-4-FLUORO-5-[(1-METHYL-1H-IMIDAZOL-2-YL)SULFANYL]-N-(1,3-THIAZOL-2-YL)BENZAMIDE
|
- Maturity onset diabetes of the young (MODY)
- Permanent neonatal diabetes mellitus (PNDM)
|
Novel |
HOXA2 |
homeobox A2 |
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Regulation of expression of SLITs and ROBOs
|
|
|
Novel |
INHBA |
inhibin subunit beta A |
- Signaling by Activin
- Signaling by Activin
- Glycoprotein hormones
- Antagonism of Activin by Follistatin
|
|
|
|
ARF1 |
ADP ribosylation factor 1 |
- Synthesis of PIPs at the plasma membrane
- Synthesis of PIPs at the Golgi membrane
- Nef Mediated CD4 Down-regulation
- trans-Golgi Network Vesicle Budding
- MHC class II antigen presentation
- Lysosome Vesicle Biogenesis
- Golgi Associated Vesicle Biogenesis
- COPI-mediated anterograde transport
- COPI-dependent Golgi-to-ER retrograde traffic
- Intra-Golgi traffic
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
|
- 1,3-Propanediol
- Guanosine-3'-monophosphate-5'-diphosphate
- Guanosine-5'-Triphosphate
- Guanosine-5'-Diphosphate
- Brefeldin A
- Myristic acid
- Glycerin
|
|
|
CALM1 |
calmodulin 1 |
- CaMK IV-mediated phosphorylation of CREB
- CaMK IV-mediated phosphorylation of CREB
- Calmodulin induced events
- Cam-PDE 1 activation
- CaM pathway
- Platelet degranulation
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- PKA activation
- DARPP-32 events
- Synthesis of IP3 and IP4 in the cytosol
- Calcineurin activates NFAT
- Calcineurin activates NFAT
- eNOS activation
- Transcriptional activation of mitochondrial biogenesis
- Inactivation, recovery and regulation of the phototransduction cascade
- Inactivation, recovery and regulation of the phototransduction cascade
- Stimuli-sensing channels
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- Ca2+ pathway
- Reduction of cytosolic Ca++ levels
- Sodium/Calcium exchangers
- Unblocking of NMDA receptors, glutamate binding and activation
- CREB1 phosphorylation through the activation of Adenylate Cyclase
- CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
- CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
- Ras activation upon Ca2+ influx through NMDA receptor
- Smooth Muscle Contraction
- Smooth Muscle Contraction
- Activation of Ca-permeable Kainate Receptor
- Uptake and function of anthrax toxins
- VEGFR2 mediated vascular permeability
- VEGFR2 mediated cell proliferation
- Phase 0 - rapid depolarisation
- Ion homeostasis
- CLEC7A (Dectin-1) induces NFAT activation
- CLEC7A (Dectin-1) induces NFAT activation
- RHO GTPases activate IQGAPs
- RHO GTPases activate PAKs
- RHO GTPases activate PAKs
- RAF activation
- RAF/MAP kinase cascade
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Glycogen breakdown (glycogenolysis)
- Glycogen breakdown (glycogenolysis)
- Protein methylation
- Extra-nuclear estrogen signaling
- Loss of phosphorylation of MECP2 at T308
- Regulation of MECP2 expression and activity
- Ion transport by P-type ATPases
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Activation of RAC1 downstream of NMDARs
- Activation of RAC1 downstream of NMDARs
- Activation of AMPK downstream of NMDARs
- Long-term potentiation
- Long-term potentiation
- RAS processing
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated IL10 synthesis
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Chlorpromazine
- Cinchocaine
- Nicardipine
- Fluphenazine
- Isoflurane
- Trifluoperazine
- Loperamide
- Perphenazine
- Phenoxybenzamine
- Felodipine
- Melatonin
- Promethazine
- Pimozide
- Nifedipine
- Bepridil
- Calcium
- Aprindine
- Deacetoxyvinzolidine
- tert-butanol
- Trimethyllysine
- N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
- Prenylamine
- Flunarizine
- (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE
- Myristic acid
- Calcium citrate
- Calcium citrate
- Calcium citrate
- Calcium Phosphate
- Calcium Phosphate
- Calcium Phosphate
- Calcium levulinate
- Calcium phosphate dihydrate
- Calcium phosphate dihydrate
- Calcium phosphate dihydrate
|
|
|
CNKSR2 |
connector enhancer of kinase suppressor of Ras 2 |
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
|
|
|
|
CTCF |
CCCTC-binding factor |
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
|
|
|
|
EXOC1 |
exocyst complex component 1 |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Insulin processing
- VxPx cargo-targeting to cilium
|
|
|
|
EXOC2 |
exocyst complex component 2 |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Insulin processing
- VxPx cargo-targeting to cilium
|
|
|
|
EXOC3 |
exocyst complex component 3 |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Insulin processing
- VxPx cargo-targeting to cilium
|
|
|
|
EXOC4 |
exocyst complex component 4 |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Insulin processing
- VxPx cargo-targeting to cilium
|
|
|
|
EXOC5 |
exocyst complex component 5 |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Insulin processing
- VxPx cargo-targeting to cilium
|
|
|
|
EXOC6B |
exocyst complex component 6B |
|
|
|
|
EXOC7 |
exocyst complex component 7 |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Insulin processing
- VxPx cargo-targeting to cilium
|
|
|
|
EXOC8 |
exocyst complex component 8 |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Insulin processing
- VxPx cargo-targeting to cilium
|
|
|
|
FLNA |
filamin A |
- Platelet degranulation
- GP1b-IX-V activation signalling
- Cell-extracellular matrix interactions
- RHO GTPases activate PAKs
- OAS antiviral response
|
|
- Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
- Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia
- Periventricular nodular heterotopia (PVNH)
- FG syndrome (FGS); Opitz-Kaveggia syndrome
|
|
GLS2 |
glutaminase 2 |
- Glutamate Neurotransmitter Release Cycle
- TP53 Regulates Metabolic Genes
- Glutamate and glutamine metabolism
|
|
|